This study aimed to investigate the use of combined-modality radiation treatment (CRT) in the treatment of prostate cancer (PCa). This study found that CRT is an effective treatment for PCa. 

This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients.

This phase 3 trial is examining the effectiveness and safety of niraparib (Zejula) in combination with abiraterone acetate (Zytiga) and prednisone (Deltasone) vs abiraterone acetate and prednisone plus placebo for patients with metastatic prostate cancer. The main outcome to be measured will be the survival time without cancer growing or spreading.

Prostate cancer is cancer that starts in the prostate gland (figure 1). The prostate gland is a small, walnut-sized structure that makes up part of a man's reproductive system by producing fluid that is part of semen. It sits below the bladder and in front of the rectum, and forms a ring around the urethra, the tube that carries urine out of the body.

Prostate cancer occurs most often in men older than 50. Although prostate cancer is very common, most men do not die from it. This is because prostate cancer usually grows very slowly.